関連する実験動画

Updated: Jun 9, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

PICALM 遺伝子変異は,アルツハイマー病のタンパク質レベルやタウの拡散に影響を与えることなく,mRNA発現を変化させる

Kunie Ando1, Lidia Lopez-Gutierrez1, Salwa Mansour2

  • 1Alzheimer and Other Tauopathies Research Group, ULB Center for Diabetes Research, Medical Faculty, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), 808 Route de Lennik, B-1070 Brussels, Belgium.

Cells
|February 12, 2026
PubMed
まとめ

アルツハイマー病 アルツハイマー病 アルツハイマー病

キーワード:
アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,GWAS GWASは,GWASという名前で呼ばれています.ピカルム (PICALM) とはSNPとは,SNPとは,SNPとはアルギロフィール粒子は,神経線維細胞の絡み合いペアリングされた螺旋状フィラメント.プリオンのようなタウの伝播である.qPCRRは,qPCRRは,qPCRは,qPCRは,qPCRは,qPCRは,qPCRは,qPCRは,qPCRはタウ・タウ・タウとは

さらに関連する動画

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes09:12

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes

Published on: December 20, 2019

Using Live-Cell Imaging to Measure the Effects of Pathological Proteins on Axonal Transport in Primary Hippocampal Neurons10:38

Using Live-Cell Imaging to Measure the Effects of Pathological Proteins on Axonal Transport in Primary Hippocampal Neurons

Published on: December 22, 2023

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...